GlassScriptPhysician profile
Saisree Ravi
NPI 1629771852
$881.58
in general payments reported to CMS, 2019-2025
12 companies · $882 in 2025
The $882 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $200.74 | 2025 | |
| Springworks Therapeutics, INC. | $149.88 | 2025 | Gomekli |
| Genentech USA, INC. | $125.04 | 2025 | Ocrevus Zunovo, Evrysdi, Enspryng |
| Argenx US, INC. | $74.47 | 2025 | Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $61.98 | 2025 | Nuplazid |
| Ucb, INC. | $61.97 | 2025 | Rystiggo |
| Grifols USA, LLC | $58.74 | 2025 | Gamunex-C |
| Csl Behring | $44.24 | 2025 | Hizentra |
| Eisai INC. | $33.78 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.93 | 2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $23.69 | 2025 | Wainua |
| Biogen, INC. | $22.12 | 2025 | Spinraza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saisree Ravi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.